Mizuho Reiterates Buy on Terns Pharma, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharma (NASDAQ:TERN) and maintained a $16 price target.
June 27, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharma and maintained a $16 price target.
The Buy rating and maintained price target by Mizuho analyst Graig Suvannavejh indicate a positive outlook for Terns Pharma. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100